San Francisco Otolaryngology selected 2bPrecise, a precision medicine data delivery platform, as its foundation for precision medicine strategy, according to a Nov. 11 press release.
The practice will start its focus with pharmacogenomics and may expand to additional genetic testing, the release said. A pilot pharmacogenomics program is underway, and access to all patients is expected for the next year.
"Our interest in precision medicine focuses on general patient wellness," Jacob Johnson, MD, president of San Francisco Otolaryngology, said in the release. "We find the drugs patients take have an important effect on the main variables we assess: whether they are able to exercise, are cognitively intact, engage in social interaction and are safe from falling."
Read the full release here.